Dr. Brian Druker
I've won the following awards
Top Doctors, Portland Monthly Magazine
Ernest Beutler Prize, American Society of Hematology
Stanley J. Korsmeyer Award, American Society for Clinical Investigation
Vollum Award (Science & Technology), Reed College
Doctor of Science, Honorary Degree, Washington University (St. Louis)
Top Doctors, Portland Monthly Magazine
35th Jeffrey A. Gottlieb Memorial Award, University of Texas M.D. Anderson Cancer Center
Pasarow Foundation Cancer Award, The Robert J. and Claire Pasarow Foundation
Lasker-DeBakey Clinical Medical Research Award, Albert and Mary Lasker Foundation
European Inventor of the Year 2009, Industry, European Patent Office and European
Hope Funds Award of Excellence: Clinical Development, The Hope Funds for Cancer Research
The Rowley Prize, International CML Foundation
Bodini Foundation Prize for Scientific Excellence in Medicine, American-Italian Cancer Foundation
Meyenburg Award for Cancer Research, Meyenburg Foundation (Heidelberg, Germany)
13th Annual Alfred G. Knudson Award in Cancer Genetics, National Cancer Institute
2006-2007 Teaching Excellence Award, OHSU School of Medicine
Keio Medical Science Prize, Keio University Medical Science Fund (Tokyo, Japan)
Golden Plate Award, Academy of Achievement
STAR Medical Research Award, Angel Foundation
Robert-Koch Prize, Robert Koch Foundation (Cologne, Germany)
Biotech Hall of Fame Award for Scientific Achievement, The Biotech Meeting
David Nathans Memorial Award, Van Andel Institute
Doctor of Science, Honorary Degree, State University of New York
Dr. Alvin J. Thompson Award, Northwest Association for Biomedical Research
Humanitarian Award, The Life Raft Group
Naomi M. Kanof Clinical Investigator Award, The Society for Investigative Dermatology
Days of Molecular Medicine Translational Medicine Award, UC San Diego-Nature Medicine
Braunschweig Preis, City of Braunschweig
David A. Karnofsky Award, American Society of Clinical Oncology
Medal of Honor, American Cancer Society
International Citizen Award, Oregon Consular Corps
Novartis-Drew University Award in Biomedical Research, Novartis-Drew University
City of Medicine Award, Durham Health Partners, Inc.
Charles F. Kettering Prize, General Motors Cancer Research Foundation
Pioneer of Survivorship Carpe Diem Award, Lance Armstrong Foundation
Alexandra J. Kefalides Prize for Leukemia Research, University of Pennsylvania Cancer Center
Donald Ware Waddell Award Lecture, Arizona Cancer Center
Warren Alpert Foundation Prize, Harvard Medical School
Emil J. Freireich Award, The University of Texas MD Anderson Cancer Center
AACR-Richard and Hinda Rosenthal Foundation Award, American Association for Cancer Research
Charles Rodolphe Brupbacher Prize for Cancer Research, Charles Rodolphe Brupbacher Stiftung
Dameshek Prize, The American Society of Hematology
John J. Kenny Award, The Leukemia and Lymphoma Society
Distinguished Faculty Award for Outstanding Research, OHSU Foundation & Faculty Senate
Lifetime Achievement Award, The Leukemia and Lymphoma Society, Washington Chapter
Outstanding Alumnus, University of California, San Diego
Discovery Award, Oregon Health Sciences Foundation
President's Undergraduate Research Award, University of California, San Diego
BCR-ABL1 compound mutations in tyrosine kinase inhibitor resistant CML: frequency and clonal relationships.
Blood., Dec (2012)
The selective Syk inhibitor P505-15 inhibits B cell signaling and function in vitro and in vivo, and augments the activity of fludarabine in chronic lymphocytic leukemia.
J. Pharmacol. Exp. Ther., Dec (2012)
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
N. Engl. J. Med., Nov;367(22):2075-88 (2012)
Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia.
Cancer Cell., Nov;22(5):656-67 (2012)
Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening.
Cancer Res., Oct (2012)
An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma.
Biochem. Biophys. Res. Commun., Sep;426(3):363-8 (2012)
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
Blood., Nov;120(19):3898-905 (2012)
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
Blood., Sep;120(13):2658-68 (2012)
A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.
Neoplasia., Jun;14(6):547-58 (2012)
FANCL ubiquitinates Î²-catenin and enhances its nuclear function.
Blood., Jul;120(2):323-34 (2012)
Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia.
Genome Res., Oct;22(10):1833-44 (2012)
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
Haematologica., May;97(5):731-8 (2012)
Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.
Br. J. Haematol., May;157(4):507-10 (2012)
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Cancer Cell., Dec;20(6):715-27 (2011)
In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.
Pediatr Blood Cancer., Sep;59(3):576-9 (2012)
Targeting survivin and p53 in pediatric acute lymphoblastic leukemia.
Leukemia., Apr;26(4):623-32 (2012)
Will imatinib compromise reproductive capacity?
Oncologist., 16(10):1422-7 (2011)
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.
J. Exp. Med., Oct;208(11):2163-74 (2011)
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Blood., Nov;118(19):5250-4 (2011)
TNFÎ± facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.
Blood., Dec;118(24):6392-8 (2011)